Natera, Inc. (NTRA) financials
NASDAQ · Healthcare · Medical - Diagnostics & Research · 6,138 employees · CEO Steven Leonard Chapman
- Price
- $414.30 -4.98%
- Market cap
- $59.7B
- Enterprise value
- $58.9B
- Last report
- Q2 '26 filed 2026-08-07
- Next report
- 2026-11-05 EPS est. -$0.28
Revenue (TTM)$2.71B+37.8% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)-10.7%+4.2 pp vs a year agoOperating income -$290M
Net income (TTM)-$192M+24.0% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$71.7M-31.4% vs a year agoCapex $157M
Diluted EPS (TTM)-$1.36+28.8% vs a year agoSum of the last 4 quarters
Net cash$853M+4.0% vs a year agoCash + short-term investments - debt
Valuation & key figures
- Market cap
- $59.7B EV $58.9B
- Revenue
- $2.71B Trailing 12 months
- Revenue growth
- +26% FY2026 consensus
- Profit margin
- -7.1% Net income / revenue, TTM
- P/E
- -304.6× Forward -284.9× (FY2026)
- P/S
- 22.1× Price / sales, TTM
- EV / EBITDA
- -329.4× TTM
- Free cash flow
- $71.7M Trailing 12 months
- Net income
- -$192M Trailing 12 months
- Revenue estimate
- $2.91B FY2026 consensus
- Earnings
- 2026-11-05 Revenue est. $708M
- Dividend
- – No dividend
Key takeaways
Computed from the reported numbers - every statement carries the figure it rests on.
- Last report (2026-08-06): revenue beat by 13.8%, EPS beat by 4.8%Revenue $753M vs $661M expected (+13.8%); EPS -$0.47 vs -$0.49 (+4.8%).
- Revenue growth accelerating: 37.7% year on yearQ2 '26 revenue $753M, against an average of 36.4% over the four quarters before.
- Operating margin -10.7% (TTM), +4.2 pp on a year agoOperating income grew 1.3% while revenue grew 37.8%.
- Capex 5.8% of revenue (a year ago 4.2%)$157M invested in the last 4 quarters (+90.6% on a year earlier). Free cash flow $71.7M.
- Diluted share count up 5.1% in a year143M diluted shares in Q2 '26, 136M a year earlier.
- Net cash $853MCash + short-term investments $1.09B, debt incl. leases $238M; a year ago net cash $820M.
Last quarter: Q2 '26
Quarter ended 2026-06-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.
Quarter vs a year ago
| Q2 '26 | Year ago | Change | |
|---|---|---|---|
| Revenue | $753M | $547M | +37.7% |
| Gross margin | 64.5% | 63.5% | +1.0 pp |
| Operating income | -$75.8M | -$110M | +31.3% |
| Operating margin | -10.1% | -20.2% | +10.1 pp |
| Net income | -$67M | -$101M | +33.7% |
| Diluted EPS | -$0.47 | -$0.74 | +36.5% |
| Operating cash flow | $54.8M | $37.6M | +45.8% |
| Capex | $63.4M | $25.9M | +144.9% |
| Free cash flow | -$8.64M | $11.7M | -174.0% |
| R&D | $228M | $146M | +55.8% |
| Stock-based compensation | $103M | $93.4M | +10.4% |
Reported vs consensus
2026-08-06| Actual | Consensus | vs consensus | |
|---|---|---|---|
| Revenue | $753M | $661M | +13.8% |
| EPS (as estimated) | -$0.47 | -$0.49 | +4.8% |
From the report of 2026-08-06 for Q2 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.
EPS vs consensus
last 8 reportsRevenue
Where the money comes from - by business line and by region, quarter by quarter.
Revenue, operating income and growth
quarterlyRevenue by business line
stacked, quarterly| Segment | Q2 '26 | y/y | Share | TTM | TTM y/y | 12 quarters |
|---|---|---|---|---|---|---|
| Product | $748M | +37.4% | 100.0% | $2.69B | +13.9% | |
| Licensing and other | – | – | – | – | – | |
| Oncology | $300K | – | 0.0% | – | – |
Revenue by region
share of total| Segment | Q2 '26 | y/y | Share | TTM | TTM y/y | 12 quarters |
|---|---|---|---|---|---|---|
| United States | $739M | – | 98.2% | – | – | |
| United States | – | – | – | – | – | |
| EMEA | $9.02M | – | 1.2% | – | – | |
| Europe, Middle East, India, Africa | – | – | – | – | – | |
| Americas, excluding U.S. | – | – | – | – | – | |
| Asia Pacific and Other | – | – | – | – | – | |
| Americas, Excluding United States | $2.22M | – | 0.3% | – | – | |
| Asia Pacific And Other | $2.05M | – | 0.3% | – | – |
Margins & cost structure
How much of each unit of revenue is left at each level - and where the costs go.
Margins
quarterlyCosts as % of revenue
quarterlyCash flow & capital allocation
Cash generated, what it is spent on, and what reaches shareholders.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsLast 4 quarters
cash flow statement- Operating cash flow
- $228M
- Capex
- -$157M
- Buybacks
- $0
- Dividends
- $0
- Acquisitions
- -$16M
- Net debt issued
- $0
- Stock-based compensation
- $381M
- Free cash flow
- $71.7M
- Returned to shareholders / FCF
- -0.0%
Share count and EPS
quarterly, dilutedBalance sheet
Liquidity, investments and debt at each quarter end.
Cash, investments and debt
quarter endsValuation & returns
Today's multiples against the company's own last five fiscal years; analyst targets and ratings.
Multiples and returns
TTM vs 5 fiscal years| Now | 5y average | Where today sits in the 5-year range | |
|---|---|---|---|
| P/E (TTM) | -304.6× | – | – |
| EV / EBITDA | -329.4× | – | – |
| EV / Sales | 21.7× | 9.9× | 4.8× – 14.0× |
| Price / FCF | 832.9× | 286.1× 2 of 5 years | 285.1× – 287.1× |
| Price / Book | 32.6× | 12.6× | 5.6× – 18.3× |
| FCF yield | 0.1% | -4.0% | -12.1% – 0.4% |
| Return on invested capital | -10.0% | -30.6% | -46.2% – -11.1% |
| Return on equity | -11.7% | -46.9% | -77.6% – -12.2% |
Analysts
Consensus target $386.00 (-6.8%)
range $245.00 – $500.00 · rating Buy
Strong buy0
Buy25
Hold3
Sell0
Strong sell0
Outlook
Analyst consensus for the coming fiscal years and what it implies at today's price.
Consensus estimates
| Fiscal year | Revenue | Growth | EPS | Growth | P/E at today's price | Analysts (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $2.91B | +26.2% | -$1.45 | +4.3% | -284.9× | 13 |
| FY2027 | $3.52B | +20.9% | -$0.37 | +74.6% | -1,122.2× | 12 |
| FY2028 | $4.26B | +21.1% | $1.27 | +445.3% | 325.0× | 16 |
| FY2029 | $5.13B | +20.5% | $2.14 | +68.1% | 193.3× | 13 |
| FY2030 | $6.19B | +20.5% | $3.65 | +70.2% | 113.6× | 13 |
Financial statements
Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.
Every reported line
All 235 figures Natera, Inc. tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).
| Line (SEC label) | Latest quarter | Year ago | y/y | Latest FY | Prior FY | y/y |
|---|---|---|---|---|---|---|
| $890K | $1.03M | -13.5% | – | – | – | |
| Accounts Payable, Current | $75.2M | $36.9M | +103.8% | $33.2M | $34.9M | -5.1% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $422M | $309M | +36.5% | $297M | $314M | -5.6% |
| Accounts Receivable, Allowance for Credit Loss | $8.02M2025-12-31 | $7.26M | +10.5% | $8.02M | $7.26M | +10.5% |
| Accounts Receivable, Allowance for Credit Loss, Current | $6.53M | $7.82M | -16.6% | $8.02M | $7.26M | +10.5% |
| Accounts Receivable, Credit Loss Expense (Reversal) | – | – | – | $1.61M | $1.28M | +25.6% |
| Accrued Bonuses, Current | $48.9M2025-12-31 | $32.2M | +51.8% | $48.9M | $32.2M | +51.8% |
| Accrued Insurance | $9.66M | $9.7M | -0.4% | $9.51M | $11.3M | -15.7% |
| Accrued Marketing Costs, Current | $26.2M | $16.6M | +58.4% | $20.2M | $16.5M | +22.2% |
| Accrued Professional Fees | $53.8M | $84.7M | -36.5% | $56.1M | $54.2M | +3.4% |
| Accrued Sales Commission, Current | $19.4M2025-12-31 | $14.2M | +36.5% | $19.4M | $14.2M | +36.5% |
| Accrued Vacation, Current | $4.7M2025-12-31 | $3.83M | +22.8% | $4.7M | $3.83M | +22.8% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $133M | $91.7M | +45.5% | $111M | $78.4M | +41.7% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$108K | -$287K | +62.4% | -$258K | -$344K | +25.0% |
| Additional Paid in Capital, Common Stock | $4.75B | $3.98B | +19.3% | $4.49B | $3.76B | +19.3% |
| Advertising Expense | – | – | – | $10.6M | $2.3M | +360.9% |
| Amortization of Debt Discount (Premium) | – | – | – | $991K2024-12-31 | $1.29M | -23.3% |
| Amortization of Intangible Assets | $5.7M | $0 | – | $3.9M | $1M | +290.0% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | -972K | -553K | -75.8% | 12.5M | 14.5M | -14.1% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $102M | $94.1M | +8.4% | $357M | $277M | +29.1% |
| APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition | $0 | $812K | -100.0% | $32.9M | $24.1M | +36.6% |
| Asset Impairment Charges | $0 | $0 | – | $02021-12-31 | – | – |
| Assets | $2.66B | $1.76B | +51.2% | $2.4B | $1.66B | +44.4% |
| Assets, Current | $1.66B | $1.43B | +15.9% | $1.5B | $1.38B | +8.8% |
| Assets, Fair Value Disclosure | $1.11B | – | – | – | – | – |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | -$5.57M | $0 | – | – | – | – |
| Business Combination, Contingent Consideration, Liability | $121M | – | – | – | – | – |
| Business Combination, Contingent Consideration, Liability, Current | $22.8M | – | – | $21.6M | – | – |
| Business Combination, Contingent Consideration, Liability, Noncurrent | $97.7M | – | – | $96.8M | – | – |
| Capitalized Computer Software, Net | $31.2M2025-12-31 | $17.1M | +82.5% | $31.2M | $17.1M | +82.5% |
| Cash and Cash Equivalents, Fair Value Disclosure | $1.09B | – | – | – | – | – |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $1.09B | $1B | +9.1% | $1.08B | $946M | +13.8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | $34.7M2025-12-31 | $52.7M | -34.2% | $131M | $303M | -57.0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $3.57M | $26.3M | -86.4% | – | – | – |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| Common Stock, Shares Authorized | 750M | 750M | 0.0% | 750M | 750M | 0.0% |
| Common Stock, Shares, Issued | 144M | 137M | +5.0% | 140M | 133M | +5.3% |
| Common Stock, Shares, Outstanding | 144M | 137M | +5.0% | 140M | 133M | +5.3% |
| Common Stock, Value, Issued | $14K | $14K | 0.0% | $14K | $12K | +16.7% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$66.9M | -$101M | +33.8% | -$208M | -$188M | -10.9% |
| Contract with Customer, Liability | $56.6M | $38.1M | +48.8% | $42M | $36.6M | +14.7% |
| Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized | -$11.8M | -$3.93M | -200.6% | -$25.9M | -$20.9M | -23.8% |
| Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress | -$11.8M | -$5.49M | -114.5% | -$19.2M | -$13.7M | -40.2% |
| Contract with Customer, Liability, Current | $40.6M | $21.6M | +88.2% | $24.9M | $19.8M | +26.1% |
| Contract with Customer, Liability, Noncurrent | $16.1M | $16.5M | -2.5% | $17.1M | $16.8M | +1.3% |
| Costs and Expenses | $829M | $657M | +26.1% | $2.62B | $1.92B | +36.3% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $200K | – | – |
| Debt Conversion, Converted Instrument, Amount | – | – | – | $287M2024-12-31 | – | – |
| Debt Instrument, Collateral Amount | $150M | $150M | 0.0% | $150M | $150M | 0.0% |
| Debt Securities, Available-for-sale | $1.09B | – | – | – | – | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $0 | – | – | – | – | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $0 | – | – | – | – | – |
| Debt Securities, Available-for-sale, Allowance for Credit Loss | $0 | $0 | – | $02024-12-31 | $0 | – |
| Debt Securities, Available-for-sale, Amortized Cost | $1.09B | – | – | – | – | – |
| Debt Securities, Available-for-sale, Current | $1M2025-09-30 | $29.5M | -96.6% | – | – | – |
| Debt Securities, Available-for-sale, Unrealized Loss Position | – | – | – | $17.7M2024-12-31 | $115M | -84.7% |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | – | – | – | $330K2024-12-31 | $2.75M | -88.0% |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions | – | – | – | 6 position2024-12-31 | 19 position | -68.4% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $51.7M | – | – |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $9M | – | – |
Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-02